Dyne Therapeutics Inc Ordinary Shares DYN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DYN is a good fit for your portfolio.
News
-
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
-
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
-
Dyne Therapeutics Announces CEO Transition
-
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
-
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
-
Dyne Therapeutics to Present at February Investor Conferences
-
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results
-
Dyne Therapeutics Gets New FDA Orphan Drug Designation
Trading Information
- Previous Close Price
- $25.44
- Day Range
- $24.93–25.92
- 52-Week Range
- $6.40–30.27
- Bid/Ask
- $14.20 / $27.58
- Market Cap
- $2.15 Bil
- Volume/Avg
- 915,656 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 141
- Website
- https://www.dyne-tx.com
Comparables
Valuation
|
Metric
|
DYN
|
CBAY
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 16.75 | 12.65 | 1.51 |
Price/Sales | — | 111.01 | 442.25 |
Price/Cash Flow | — | — | — |
Price/Earnings
DYN
CBAY
PLRX
Financial Strength
|
Metric
|
DYN
|
CBAY
|
PLRX
|
|---|---|---|---|
Quick Ratio | 2.41 | 10.70 | 17.43 |
Current Ratio | 2.53 | 10.96 | 17.72 |
Interest Coverage | — | −5.27 | −145.34 |
Quick Ratio
DYN
CBAY
PLRX
Profitability
|
Metric
|
DYN
|
CBAY
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −88.69% | −30.06% | −22.68% |
Return on Equity (Normalized) | −114.25% | −51.97% | −24.50% |
Return on Invested Capital (Normalized) | −102.56% | −30.87% | −28.46% |
Return on Assets
DYN
CBAY
PLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gwrkgcjlh | Mvp | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qgjwvwqt | Fgbcyv | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Krnspmwd | Grrvscc | $99.5 Bil | |
MRNA
| Moderna Inc | Lwpsbzrf | Gqf | $38.8 Bil | |
ARGX
| argenx SE ADR | Znwbbymyv | Vqhws | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Tqxhyfdj | Dsbzj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vvtcvtzcv | Qrrmcb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cwzncrccc | Rbhskc | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zwzlfmfffc | Htwkrq | $12.5 Bil | |
INCY
| Incyte Corp | Tnnwcxpp | Xrsny | $11.6 Bil |